Advancing industrialized Microcrystal Electron Diffraction (MicroED) capabilities for global drug development<\/i><\/p>\n
SUZHOU, China<\/span>, April 16, 2026<\/span> \/PRNewswire\/ —\u00a0Crystal\u00a0Pharmatech is a science-driven CRO\/CDMO specializing in solid-state research, preformulation studies, and formulation development and manufacturing for small molecule drugs. The company operates a global network of R&D and manufacturing sites across the United States, Canada, and China, providing specialized services to clients worldwide. On April 14th<\/span>, the company announced the introduction of the\u00a0ELDICO ED-1 microcrystal electron diffractometer, <\/b>along with the further expansion of its strategic collaboration with ELDICO Scientific AG.<\/p>\n With this milestone, Crystal Pharmatech will become the first company in both China and the Asia-Pacific region to deploy a dedicated MicroED (Microcrystal Electron Diffraction) platform purpose-built for industrial applications, with the ED-1 to be installed at its Suzhou, China R&D site and made available to global clients worldwide. Beyond deployment, the company is advancing the integration of MicroED into routine solid-state workflows, transforming a historically specialized technique into a scalable, high-throughput platform for pharmaceutical development.<\/p>\n This investment represents a significant advancement in Crystal Pharmatech’s mission to industrialize next-generation solid-state characterization technologies and deliver faster, more reliable, and structurally informed insights for drug development programs worldwide \u2014 expanding access to industrial-grade MicroED capabilities for its global partners.<\/p>\n Unlike conventional approaches that rely on adapted transmission electron microscopes (TEMs), the ELDICO ED-1 is the world’s first dedicated electron diffractometer, purpose-built to determine crystal structures directly from sub-micron crystalline powders for small-molecule compounds.<\/p>\n Designed for real-world pharmaceutical development, the ED-1 supports automated, 24\/7 operation with streamlined data acquisition and high reproducibility. This transforms MicroED from a specialized, expert-dependent technique into a scalable, high-throughput analytical platform suitable for routine industrial workflows.<\/p>\n Through this collaboration, Crystal Pharmatech will further strengthen its capabilities in:<\/p>\n “Integrating the ELDICO ED-1 into our platform represents a major step toward making MicroED a routine tool in pharmaceutical development,” said Alex Chen, Co-founder, Chairman & CEO of Crystal Pharmatech. “As the first company in China and the Asia\u2013Pacific region to deploy this dedicated technology, we are advancing our commitment to delivering next-generation, industrialized solid-state solutions to global partners. A long-standing aspiration in solid-state science\u2014to determine the crystal structure of every polymorph\u2014is now becoming increasingly achievable. Leveraging our deep expertise in crystallography and solid-state research, we will integrate the ED-1 into routine polymorph, salt, and cocrystal screening workflows, with the goal of elucidating the structure of every form identified.”<\/p>\n The collaboration builds on an established partnership between Crystal Pharmatech and ELDICO Scientific AG, particularly in solid-state research and advanced crystallography applications.<\/p>\n “Crystal Pharmatech is an ideal partner to bring MicroED into industrial practice,” said James Berwick, CEO of ELDICO Scientific AG. “Their deep expertise in solid-state science and strong track record in supporting global pharmaceutical development uniquely position them to unlock the full potential of the ED-1 platform.”<\/p>\n With this milestone, Crystal Pharmatech continues to strengthen its leadership in solid-state research, reinforcing its position as a trusted partner for pharmaceutical companies seeking high-quality, industrial-grade analytical solutions across the drug development lifecycle.<\/p>\n About Crystal Pharmatech<\/b><\/p>\n Crystal Pharmatech is a science-driven CRO\/CDMO specializing in solid-state research, preformulation, and formulation development for small-molecule drugs. Leveraging deep expertise in crystallization and solid-form science, the company addresses critical developability challenges related to bioavailability, stability, and manufacturability.<\/p>\n Founded in 2010, Crystal Pharmatech provides integrated support across the drug development lifecycle\u2014from early developability assessment and solid-form screening to formulation development and clinical-to-commercial manufacturing\u2014through its global network of R&D and manufacturing sites in the United States, Canada, and China. To date, the company has supported more than 2,000 clients<\/b> and contributed to over 4,000 compounds<\/b> worldwide.<\/p>\n Guided by its Molecule\u2013Material\u2013Medicine (M3)<\/b> framework, the company enables First-Time-Right<\/b> development, reducing risk and accelerating timelines for its global partners.<\/p>\n About ELDICO Scientific AG<\/b><\/p>\n ELDICO Scientific AG is a technology company headquartered in Basel, Switzerland, dedicated to advancing the application of electron diffraction in structural analysis. Its flagship ED-1 platform supports routine MicroED applications for sub-micron crystalline materials across the pharmaceutical, chemical, and materials science industries. As the world’s first industrial-grade microcrystal electron diffractometer, the ED-1 is purpose-built to enable direct crystal structure determination of small molecule compounds from sub-micron crystalline powders.<\/p>","protected":false},"excerpt":{"rendered":" <\/p>\n Advancing industrialized Microcrystal Electron Diffraction (MicroED) capabilities for global drug development<\/i><\/p>\n SUZHOU, China<\/span>, April 16, 2026<\/span> \/PRNewswire\/ —\u00a0Crystal\u00a0Pharmatech is a science-driven CRO\/CDMO specializing in solid-state research, preformulation studies, and formulation development and manufacturing for small molecule drugs. The company operates a global network of R&D and manufacturing sites across the United States, Canada, and China, providing specialized services to clients worldwide. On April 14th<\/span>, the company announced the introduction of the\u00a0ELDICO ED-1 microcrystal electron diffractometer, <\/b>along with the further expansion of its strategic collaboration with ELDICO Scientific AG.<\/p>\n With this milestone, Crystal Pharmatech will become the first company in both China and the Asia-Pacific region to deploy a dedicated MicroED (Microcrystal Electron Diffraction) platform purpose-built for industrial applications, with the ED-1 to be installed at its Suzhou, China R&D site and made available to global clients worldwide. Beyond deployment, the company is advancing the integration of MicroED into routine solid-state workflows, transforming a historically specialized technique into a scalable, high-throughput platform for pharmaceutical development.<\/p>\n This investment represents a significant advancement in Crystal Pharmatech’s mission to industrialize next-generation solid-state characterization technologies and deliver faster, more reliable, and structurally informed insights for drug development programs worldwide \u2014 expanding access to industrial-grade MicroED capabilities for its global partners.<\/p>\n Unlike conventional approaches that rely on adapted transmission electron microscopes (TEMs), the ELDICO ED-1 is the world’s first dedicated electron diffractometer, purpose-built to determine crystal structures directly from sub-micron crystalline powders for small-molecule compounds.<\/p>\n Designed for real-world pharmaceutical development, the ED-1 supports automated, 24\/7 operation with streamlined data acquisition and high reproducibility. This transforms MicroED from a specialized, expert-dependent technique into a scalable, high-throughput analytical platform suitable for routine industrial workflows.<\/p>\n Through this collaboration, Crystal Pharmatech will further strengthen its capabilities in:<\/p>\n “Integrating the ELDICO ED-1 into our platform represents a major step toward making MicroED a routine tool in pharmaceutical development,” said Alex Chen, Co-founder, Chairman & CEO of Crystal Pharmatech. “As the first company in China and the Asia\u2013Pacific region to deploy this dedicated technology, we are advancing our commitment to delivering next-generation, industrialized solid-state solutions to global partners. A long-standing aspiration in solid-state science\u2014to determine the crystal structure of every polymorph\u2014is now becoming increasingly achievable. Leveraging our deep expertise in crystallography and solid-state research, we will integrate the ED-1 into routine polymorph, salt, and cocrystal screening workflows, with the goal of elucidating the structure of every form identified.”<\/p>\n The collaboration builds on an established partnership between Crystal Pharmatech and ELDICO Scientific AG, particularly in solid-state research and advanced crystallography applications.<\/p>\n “Crystal Pharmatech is an ideal partner to bring MicroED into industrial practice,” said James Berwick, CEO of ELDICO Scientific AG. “Their deep expertise in solid-state science and strong track record in supporting global pharmaceutical development uniquely position them to unlock the full potential of the ED-1 platform.”<\/p>\n With this milestone, Crystal Pharmatech continues to strengthen its leadership in solid-state research, reinforcing its position as a trusted partner for pharmaceutical companies seeking high-quality, industrial-grade analytical solutions across the drug development lifecycle.<\/p>\n About Crystal Pharmatech<\/b><\/p>\n Crystal Pharmatech is a science-driven CRO\/CDMO specializing in solid-state research, preformulation, and formulation development for small-molecule drugs. Leveraging deep expertise in crystallization and solid-form science, the company addresses critical developability challenges related to bioavailability, stability, and manufacturability.<\/p>\n Founded in 2010, Crystal Pharmatech provides integrated support across the drug development lifecycle\u2014from early developability assessment and solid-form screening to formulation development and clinical-to-commercial manufacturing\u2014through its global network of R&D and manufacturing sites in the United States, Canada, and China. To date, the company has supported more than 2,000 clients<\/b> and contributed to over 4,000 compounds<\/b> worldwide.<\/p>\n Guided by its Molecule\u2013Material\u2013Medicine (M3)<\/b> framework, the company enables First-Time-Right<\/b> development, reducing risk and accelerating timelines for its global partners.<\/p>\n About ELDICO Scientific AG<\/b><\/p>\n ELDICO Scientific AG is a technology company headquartered in Basel, Switzerland, dedicated to advancing the application of electron diffraction in structural analysis. Its flagship ED-1 platform supports routine MicroED applications for sub-micron crystalline materials across the pharmaceutical, chemical, and materials science industries. As the world’s first industrial-grade microcrystal electron diffractometer, the ED-1 is purpose-built to enable direct crystal structure determination of small molecule compounds from sub-micron crystalline powders.<\/p>\n <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-53700","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/53700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53700"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/53700\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n